Elicio Therapeutics (ELTX) Non-Current Debt (2020 - 2026)

Elicio Therapeutics' (ELTX) quarterly Non-Current Debt came in at $9.5 million in Q1 2026, up 0.72% on a QoQ basis from $9.4 million in Q4 2025.

Elicio Therapeutics (ELTX) Non-Current Debt (2020 - 2026) Analysis & Trends

Elicio Therapeutics (ELTX) has 4 years of Non-Current Debt data on file, last reported at $9.5 million in Q1 2026.

Quarterly Non-Current Debt changed N/A year-over-year to $9.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.5 million (changed N/A YoY) and the FY2025 annual result came in at $9.4 million, down 53.04% from the prior year.
Non-Current Debt rose to $9.5 million in Q1 2026, from $9.4 million in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $20.0 million in Q4 2024 to a low of $9.3 million in Q2 2025.
A 3-year average of $11.6 million and a median of $9.5 million in 2026 frame the typical range for Non-Current Debt.
The widest YoY moves for Non-Current Debt: up 53.04% in 2025, down 53.04% in 2025.
Tracing ELTX's Non-Current Debt over 3 years: stood at $20.0 million in 2024, then tumbled by 53.04% to $9.4 million in 2025, then rose by 0.72% to $9.5 million in 2026.
The last three Non-Current Debt figures came in at $9.5 million (Q1 2026), $9.4 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	8.96 Bn
10	Elicio Therapeutics	58.41 Mn	34.91 Mn	-	9.54 Mn

Download Data